Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 19/20 | 0.59 |
| ▸ | PTPRA | P18433 | 2/20 | 0.48 |
| ▸ | CDC25B | P30305 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7062370 | 0.83 | PTPN1 (0.55) | PTPN1PTPRA | |
| SCHEMBL1242159 | 0.81 | PTPN1 (0.62) | PTPN1 | |
| SCHEMBL8485704 | 0.80 | PTPN1 (0.42) | PTPN1CDC25BATM | |
| SCHEMBL7064346 | 0.80 | PTPN1 (0.62) | PTPN1 | |
| SCHEMBL17197587 | 0.80 | CDC25B (0.50) | PTPN1CDC25BATM | |
| SCHEMBL4022644 | 0.78 | ALDH1A1 (0.48) | PTPN1CDC25BATM | |
| SCHEMBL7064433 | 0.77 | PTPN1 (0.65) | PTPN1 | |
| SCHEMBL7059668 | 0.76 | PTPN1 (0.57) | PTPN1PTPRA | |
| SCHEMBL7059898 | 0.76 | PTPN1 (0.55) | PTPN1PTPRA | |
| SCHEMBL7062331 | 0.75 | PTPN1 (0.60) | PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1313696-A2 | AMINO(OXO)ACETIC ACID PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ABBOTT LABORATORIES (US) | 2003-05-28 | — | — | EP | claimed |
| US-20020035137-A1 | Amino (oxo) acetic acid protein tyrosine phosphatase inhibitors | ABBOTT LABORATORIES | 2002-03-21 | — | — | US | claimed |
| WO-2002018323-A2 | AMINO(OXO)ACETIC ACID PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ABBOTT LABORATORIES (US) | 2002-03-07 | — | — | WO | claimed |
| US-7884234-B2 | N-[4-(tert-butyl)benzyl]-N-[4 -(trifluoromethoxy)biphenyl-3-yl]oxamic Acid; Inhibitors of plasminogen activator inhibitor-1 (PAI-1); thrombogenesis, fibrogenesis, accumulation of visceral fat, cell proliferation, angiogenesis | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2011-02-08 | — | — | US | disclosed |
| US-20090215899-A9 | N-Phenyloxamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-08-27 | — | — | US | disclosed |
| EP-2072498-A1 | N-PHENYLOXAMIDIC ACID DERIVATIVE | Institute of Medicinal Molecular Design, Inc. (JP) | 2009-06-24 | — | — | EP | disclosed |
| US-20080249175-A1 | N-Phenyloxamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2008-10-09 | — | — | US | disclosed |
| US-20020035137-A1 | Amino (oxo) acetic acid protein tyrosine phosphatase inhibitors | ABBOTT LABORATORIES | 2002-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249175-A1 | N-Phenyloxamide derivatives | SERPINE1, SERPINH1, F12 | PTPN1 2630/4885PTPRA 4347/4885CDC25B 3907/4885 |
| US-20020035137-A1 | Amino (oxo) acetic acid protein tyrosine phosphatase inhibitors | PPM1A, PTPRO, PTP4A1 | PTPN1 10/4885PTPRA 11/4885CDC25B 120/4885 |
| US-20090215899-A9 | N-Phenyloxamide derivatives | SERPINE1, SERPINH1, F12 | PTPN1 2630/4885PTPRA 4347/4885CDC25B 3907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.